# A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

> **NCT02604199** · PHASE2 · TERMINATED · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 58 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** ARC-520 Injection
- **OTHER:** placebo
- **DRUG:** entecavir
- **DRUG:** tenofovir
- **DRUG:** antihistamine

## Key facts

- **NCT ID:** NCT02604199
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 58 (ACTUAL)
- **Why stopped:** Company decision to discontinue trial
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02604199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02604199, "A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02604199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*